Comment - Pharmaceutical Technology

Lupus breakthrough sparks hope in a frustrating field

Chris Lo — Tue, 02 Aug 2016 17:30:00 +0000

Could copper unlock a new wave of metabolic treatments?

Lindsay — Sun, 07 Aug 2016 17:30:00 +0000

Direct-to-Consumer Genetic Tests: Testing Trends

GlobalData Thematic Intelligence — Mon, 20 Dec 2021 15:55:31 +0000

Genetic tests have traditionally been ordered and interpreted in a clinical or medical research setting.

Strong growth expected in the immunology market, 2016-2023

GBI — Thu, 05 Jul 2018 15:43:18 +0000

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5–7% of people in Western populations.

Outcome-based contracts viable for Kymriah, but US payers still unsure

GlobalData Healthcare — Mon, 30 Jul 2018 12:38:32 +0000

Novartis’ US OBCs for reimbursing Kymriah (tisagenlecleucel) for acute lymphoblastic leukaemia (ALL) remain a viable option for treatment centres

Anticoagulants drive market growth in multiple cardiovascular disease

GlobalData Healthcare — Fri, 16 Feb 2018 17:09:13 +0000

Major growth in the anticoagulant market continued through 2017, primarily due to the increasing global prevalence of multiple cardiovascular (CV) indications including atrial fibrillation, acute coronary syndrome, peripheral artery disease and venous thromboembolism. However, cheap and established anticoagulants such as warfarin and heparin continue to present a barrier for new anticoagulant entrants.

FDA approves first GMG treatment in more than 60 years

GlobalData Healthcare — Mon, 30 Oct 2017 11:32:08 +0000

Myasthenia gravis is a progressive autoimmune disease that leads to muscle weakness. This can range from eyelid drooping to severe and debilitating symptoms where respiratory and skeletal muscles are affected. As the disease becomes more severe and more muscles become affected, it is referred to as generalized myasthenia gravis (GMG).

Uncertainty Grows for Immuno-Oncology Therapies in Glioblastoma Multiform

GlobalData Healthcare — Tue, 11 Apr 2017 17:30:00 +0000

While GlobalData foresees that immunotherapies will ultimately improve the survival of GBM patients, their disappointing clinical outcome highlights that the “one-drug-fits-all” approach will not apply to GBM patients when it comes to immunotherapies.

What does Brexit mean for medical regulation?

GlobalData Healthcare — Mon, 30 Jan 2017 06:25:00 +0000

On 17 January 2017, UK Prime Minister Theresa May outlined her vision for a hard Brexit, clarifying the government’s ambitions for a post-Brexit Britain. With the European Union (Notification of Withdrawal) Bill now on its way through parliament, the official date of triggering Article 50 is swiftly approaching.

Artificial intelligence: the beginning of a new era in healthcare?

GlobalData Healthcare — Wed, 24 May 2017 07:41:00 +0000

Artificial intelligence (AI) has already started to revolutionise healthcare, but this is only the beginning of a new era – we will see an unimaginable potential coming to fruition over the next several years.

Safety concerns cloud Ocaliva’s future prospects in NASH

GlobalData Healthcare — Mon, 02 Oct 2017 11:03:21 +0000

On 21 September, the FDA issued a drug safety communication regarding the use of Intercept Pharmaceuticals’ drug, Ocaliva, in primary biliary cholangitis (PBC), a rare, chronic liver disease. According to the regulatory body, the drug was being dosed incorrectly in clinical practice, leading to serious liver injury and death in patients. A total of 19 deaths were identified, while 11 cases of serious liver injury were reported with Ocaliva use.

More treatment options are needed for paediatric eosinophilic esophagitis

GlobalData Healthcare — Wed, 22 Dec 2021 15:25:23 +0000

There are currently no late-stage pipeline agents for eosinophilic esophagitis being studied in paediatric populations, unlike those for teens and adults.

Discontinuation of Sanofi’s C. difficile vaccine program could spell good news for Pfizer and Valneva

GlobalData Healthcare — Wed, 13 Dec 2017 10:46:30 +0000

On December 1, Sanofi Pasteur announced its intention to discontinue the Phase III development program for its Clostridium difficile vaccine.

Top 20 biopharmaceutical companies hold their spot despite market cap drop in Q1 2022

GlobalData Healthcare — Tue, 03 May 2022 13:34:29 +0000

Supply chain crisis triggers deglobalisation – leading macroeconomic influencers

Vasanthi Vara — Thu, 21 Oct 2021 06:53:16 +0000

The clogging at ports is expected to cause further absence or delays in shipping, coupled with higher price tags this shopping season.

Supply chain bottlenecks and shortages riskier than Covid-19 – leading macroeconomic influencers

Vasanthi Vara — Mon, 18 Oct 2021 08:08:46 +0000

Economists believe that supply chain bottlenecks are putting pressure on prices, restricting production and growth of the US economy.

NHS crisis puts pressure on patient safety – leading macroeconomic influencers

Vasanthi Vara — Mon, 21 Jun 2021 07:34:25 +0000

Economists believe that the increase in patient numbers is exerting additional pressure on hospital beds, which have been reduced.

Cerecin engages CROs Novotech, NTA in early-phase tricaprilin trials; $10m–$20m raise ongoing with another $30m–$50m to start YE, CEO says

Sean Rai-Roche — Mon, 08 Feb 2021 08:32:07 +0000

Cerecin engages with the CROs Novotech for its Phase II tricaprilin trial for migraine prevention and NTA for a Phase I infantile spasm.

Quercis enlists Clinipace for Phase III trial in pancreatic cancer-related venous thromboembolism; in $40m-$60m fundraise, CEO says

William Newton — Fri, 05 Feb 2021 09:33:34 +0000

Quercis is working with the CRO Clinipace in a Phase III trial for venous thromboembolism prevention in pancreatic cancer patients.

Covaxx commissions CRO PPD for Phase II/III Covid-19 vaccine trial in Brazil, CEO says

William Newton — Fri, 05 Feb 2021 08:38:11 +0000

Covaxx commissions CRO PPD for Covid-19 vaccine trial beginning this quarter and also collaborating with Dasa for vaccine distribution.